Zemplar
FDA Approves Procysbi for Rare Genetic Condition »
"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...
Read the FDA Approves Procysbi for Rare Genetic Condition article »
Zemplar Injection
ZEMPLAR®
(paricalcitol) Injection
Fliptop Vial
DRUG DESCRIPTION
Paricalcitol, USP, the active ingredient in Zemplar Injection (paricalcitol injection fliptop vial) , is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease(CKD) Stage 5. Zemplar is available as a sterile, clear, colorless, aqueous solution for intravenous injection. Each mL contains paricalcitol, 2 mcg or 5 mcg and the following inactive ingredients: alcohol, 20% (v/v) and propylene glycol, 30% (v/v).
Paricalcitol is a white powder chemically designated as 19-nor-1α,3β,25-trihydroxy-9,10-secoergosta5(Z),7(E),22(E)-triene and has the following structural formula:
 |
Molecular formula is C27H44O3.
Molecular weight is 416.64.
Last reviewed on RxList: 5/20/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Zemplar Injection Information
Zemplar Injection - User Reviews
Zemplar Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Zemplar Injection sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
